A5073049150- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Metabolism, Diabetes, and Cancer
- Electrocatalysts for Energy Conversion
- Colorectal Cancer Treatments and Studies
- Advanced battery technologies research
- Gastric Cancer Management and Outcomes
- Polymer crystallization and properties
- Cancer-related Molecular Pathways
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Biochemical and Molecular Research
- Polymer Nanocomposites and Properties
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Recycling and Waste Management Techniques
- Electrochemical Analysis and Applications
- Advanced Photocatalysis Techniques
- Advanced biosensing and bioanalysis techniques
- Structural Behavior of Reinforced Concrete
- Cytokine Signaling Pathways and Interactions
- PARP inhibition in cancer therapy
- Autophagy in Disease and Therapy
- Muon and positron interactions and applications
- HER2/EGFR in Cancer Research
- Cancer-related gene regulation
- Extracellular vesicles in disease
Inner Mongolia University
2022-2025
National University of Mongolia
2025
Central South University
2022-2024
Ministry of Housing and Urban-Rural Development
2024
Chongqing University
2021-2023
Seventh People's Hospital of Shanghai
2022-2023
Hangzhou Medical College
2021-2023
Wuyi University
2022
Daping Hospital
2013-2021
Army Medical University
2013-2021
The EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have become a standard therapy in patients with EGFR-activating mutations. Unfortunately, acquired resistance eventually limits the clinical effects and application of EGFR-TKIs. Studies shown that suppression epithelial-mesenchymal transition (EMT) interleukin (IL)-6/STAT3 pathway may abrogate this mechanism drug TKIs. This study aims to investigate effect metformin on sensitizing EGFR-TKI-resistant human lung cancer cells vitro vivo...
Abstract The chloride ions in seawater result corrosion, low catalytic efficiency, and poor stability of the electrocatalysts direct electrolysis, which limits use large‐scale electrolysis technology. Herein, a corrosion‐resistant Ag/NiFeRu layered double hydroxide (LDH) electrocatalyst for at industrial current density, Ru Ag species catalyst can have corrosion‐resistance from anode surface enhance its robustness is designed. requires overpotentials 256 287 mV to obtain density 1 A cm −2 m...
Abstract Developing durable electrocatalysts with high performance for hydrogen evolution reaction (HER) in acid conditions is of prime challenge production. Durability important prerequisite catalyst application. Herein, this work constructs the Co‐doped WO 3 loaded Pt nanoparticles under ammonia treatment (Pt/N‐CoWO ) Pt‐N/O‐W interaction, which shows excellent activity and stability acidic production at industrial current density. The electronic structure species modulated enhanced Pt‐N/O...
// Li 1, * , Wenting Huang Kunlin Kejun Zhang 2 Caiyu Lin 1 Rui Han Conghua Lu Yubo Wang Hengyi Chen Fenfen Sun Yong He Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing, China Clinical Labratory, These authors have contributed equally to this work Correspondence to: He, e-mail: heyong@dphospital.tmmu.edu.cn Keywords: metformin, EGFR-TKI, pulmonary fibrosis, TGF-β Received: June 13, 2015 Accepted: October 05,...
Abstract Purpose: Preclinical and retrospective studies suggested a role for metformin in sensitizing patients who have diabetes with non–small cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitors (TKIs). We therefore examined its effects combination gefitinib without harboring mutations (EGFRm). Patients Methods: A total of 224 treatment-naïve stage IIIB–IV EGFRm NSCLC were randomly assigned 1:1 ratio receive plus either or placebo. The primary endpoint was progression-free survival...
Abstract BRCA1/2 gene mutations, which result in a dysfunction of homologous recombination repair, have been discovered at least 5% breast cancer (BC) patients with the increase BC incidence recent years. PARP inhibitors (PARPis), first drugs clinical approval based on synthetic lethality, approved to treat BRCA1/2‐mutant BC. However, as other targeted drugs, PARPis drug resistance has become significant obstacle application PARPis. In this paper, we discuss mechanism PARPis, monotherapy and...
Tungsten sulfide (WS 2 ), as a typical 2D layered material, is promising electrocatalyst for the hydrogen evolution reaction (HER), while its low electrical conductivity, limited number of active sites, and inadequate intrinsic activity restrict HER performance. Herein, reasonable construction cerium phosphate‐modified tungsten phosphide/tungsten composite nanosheets with ternary heterostructure on carbon cloth (CeP 5 O 14 /WP/WS /CC) an efficient self‐supported electrode reported....
Glycerol electrooxidation (GOR), as an innovative strategy for the production of value‐added chemicals, is considered a promising anodic alternative to oxygen evolution reaction in electrocatalysis. However, high potential and limited selectivity faradaic efficiency impede industrial‐scale application toward GOR. Herein, we first time constructed rhenium ruthenium co‐doped transition metal alloy (NiCoFeRuRe) efficient glycerol formate. Benefiting from rapid generation M3+‐OOH induced by Ru...
Glycerol electrooxidation (GOR), as an innovative strategy for the production of value-added chemicals, is considered a promising anodic alternative to oxygen evolution reaction in electrocatalysis. However, high potential and limited selectivity faradaic efficiency impede industrial-scale application toward GOR. Herein, we first time constructed rhenium ruthenium co-doped transition metal alloy (NiCoFeRuRe) efficient glycerol formate. Benefiting from rapid generation M3+-OOH induced by Ru...
Accurate determination of single exosomal inclusions in situ presents a significant challenge due to their extremely low abundance as well sub-100 nm vesicle dimensions. Here, we created Liposome Fusogenic Enzyme-free circuit (LIFE) approach for the high-fidelity identification exosome-encapsulated cargoes without destroying integrity. The probe-loaded cationic fusogenic liposome could capture and fuse with target exosome, enabling probes delivery biomolecule-initiated cascaded signal...
Although EGFR tyrosine kinase inhibitors (TKIs) have shown dramatic effects against sensitizing mutations in non-small cell lung cancer (NSCLC), ~20%-30% of NSCLC patients with EGFR-sensitive mutation exhibit intrinsic resistance to EGFR-TKIs. The purpose the current study was investigate enhanced antitumor effect metformin (Met), a biguanide drug, combination gefitinib (Gef) primary resistant human cells and associated molecular mechanism.H1975 line treated Met and/or Gef examine inhibition...
Abstract Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has sufficient clinical efficacy and satisfactory safety in ALK-positive non-small cell lung cancer (NSCLC) patients with or without brain metastasis. now become an important drug the first-line treatment of advanced NSCLC; however, resistance almost inevitable. The increased expression hepatocyte growth factor (HGF) its physiological receptor tyrosine MET have been shown to be linked acquired various...
// Hengyi Chen 1 , Yubo Wang Caiyu Lin Conghua Lu Rui Han Jiao Li and Yong He Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing, China Correspondence to: He, email: heyong8998@126.com Keywords: vorinostat, metformin, BIM, apoptosis, EGFR-TKI resistance Received: April 04, 2017 Accepted: August 17, Published: September 23, ABSTRACT There is a close relationship between low expression BIM to epidermal growth factor receptor tyrosine kinase...
The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib is a promising therapeutic option for patients with advanced non-small-cell lung cancer (NSCLC) in second-line or first-line treatment because of its applications selectively inhibiting EGFR T790M and EGFR-tyrosine kinase sensitizing mutations. However, the activation autophagy associated may play protective role NSCLC cells injury induced by osimertinib.The aim present study was to effects osimertinib-induced...
We present the rationale and study design of CGMT (combined gefitinib metformin therapy) trial (www.ClinicalTrials.gov Identifier: NCT01864681), which is aimed at treating locally advanced non-small-cell lung cancer. The a multicenter, phase II randomized, double-blinded, placebo-controlled study, designed to evaluate safety efficacy in combination with as first-line therapy patients presenting stage IIIb-IV cancer expressing epidermal growth factor receptor mutant. Two therapies are...